CALT
Income statement / Annual
Last year (2023), Calliditas Therapeutics AB (publ)'s total revenue was $1.21 B,
an increase of 50.32% from the previous year.
In 2023, Calliditas Therapeutics AB (publ)'s net income was -$466.19 M.
See Calliditas Therapeutics AB (publ),s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$1.21 B |
$802.88 M |
$229.35 M |
$874.00 K |
$184.83 M |
$0.00 |
$0.00 |
$497.00 K |
$478.00 K |
| Cost of Revenue |
$77.06 M
|
$15.20 M
|
$0.00
|
$0.00
|
$0.00
|
$51.00 K
|
$51.00 K
|
$56.52 M
|
$51.39 M
|
| Gross Profit |
$1.13 B
|
$787.68 M
|
$229.35 M
|
$874.00 K
|
$184.83 M
|
-$51.00 K
|
-$51.00 K
|
-$56.02 M
|
-$50.91 M
|
| Gross Profit Ratio |
0.94
|
0.98
|
1
|
1
|
1
|
0
|
0
|
-112.72
|
-106.51
|
| Research and Development Expenses |
$499.54 M
|
$414.75 M
|
$357.49 M
|
$241.37 M
|
$149.83 M
|
$99.26 M
|
$384.00 K
|
$40.28 M
|
$36.89 M
|
| General & Administrative Expenses |
$332.99 M
|
$259.47 M
|
$210.63 M
|
$102.76 M
|
$62.88 M
|
$133.15 M
|
$84.60 M
|
$56.41 M
|
$51.28 M
|
| Selling & Marketing Expenses |
$727.74 M
|
$515.19 M
|
$179.60 M
|
$38.96 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$1.06 B
|
$774.66 M
|
$390.23 M
|
$141.72 M
|
$62.88 M
|
$133.15 M
|
$84.60 M
|
$56.41 M
|
$51.28 M
|
| Other Expenses |
$0.00
|
$20.21 M
|
$6.09 M
|
$0.00
|
$0.00
|
$51.00 K
|
$51.00 K
|
$112.00 K
|
$111.00 K
|
| Operating Expenses |
$1.51 B
|
$1.21 B
|
$753.80 M
|
$383.10 M
|
$212.71 M
|
$133.20 M
|
$84.65 M
|
$56.52 M
|
$51.39 M
|
| Cost And Expenses |
$1.59 B
|
$1.22 B
|
$753.80 M
|
$383.10 M
|
$212.71 M
|
$133.20 M
|
$84.65 M
|
$56.52 M
|
$51.39 M
|
| Interest Income |
$29.10 M
|
$50.20 M
|
$102.00 K
|
$547.00 K
|
$926.00 K
|
$6.00 K
|
$0.00
|
$2.00 K
|
$0.00
|
| Interest Expense |
$73.20 M
|
$12.53 M
|
$7.11 M
|
$393.00 K
|
$325.00 K
|
$8.00 K
|
$2.24 M
|
$1.01 M
|
$9.00 K
|
| Depreciation & Amortization |
$16.59 M
|
$12.91 M
|
$34.43 M
|
$2.82 M
|
$1.82 M
|
$51.00 K
|
$51.00 K
|
$112.00 K
|
$111.00 K
|
| EBITDA |
-$367.80 M |
-$388.82 M |
-$471.83 M |
-$379.40 M |
-$30.35 M |
-$133.14 M |
-$84.60 M |
-$56.40 M |
-$51.28 M |
| EBITDA Ratio |
-0.3
|
-0.48
|
-2.06
|
-434.09
|
-0.16
|
0
|
0
|
-113.49
|
-107.28
|
| Operating Income Ratio |
-0.32
|
-0.53
|
-2.29
|
-434.46
|
-0.15
|
0
|
0
|
-112.72
|
-106.51
|
| Total Other Income/Expenses Net |
-$72.62 M
|
$5.39 M
|
$9.47 M
|
-$53.93 M
|
-$4.48 M
|
$1.15 M
|
-$2.29 M
|
-$395.00 K
|
$375.00 K
|
| Income Before Tax |
-$457.02 M
|
-$409.42 M
|
-$513.37 M
|
-$436.15 M
|
-$32.50 M
|
-$132.05 M
|
-$86.79 M
|
-$56.91 M
|
-$51.01 M
|
| Income Before Tax Ratio |
-0.38
|
-0.51
|
-2.24
|
-499.03
|
-0.18
|
0
|
0
|
-114.51
|
-106.72
|
| Income Tax Expense |
$9.17 M
|
$2.85 M
|
-$3.84 M
|
$360.00 K
|
$77.00 K
|
$441.00 K
|
$0.00
|
$0.00
|
$9.00 K
|
| Net Income |
-$466.19 M
|
-$412.27 M
|
-$509.54 M
|
-$436.51 M
|
-$32.58 M
|
-$132.05 M
|
-$86.79 M
|
-$56.91 M
|
-$51.01 M
|
| Net Income Ratio |
-0.39
|
-0.51
|
-2.22
|
-499.44
|
-0.18
|
0
|
0
|
-114.51
|
-106.72
|
| EPS |
-17.38 |
-15.56 |
-20.04 |
-19.46 |
-1.76 |
-5.08 |
-5.12 |
-3.42 |
-3.08 |
| EPS Diluted |
-17.38 |
-15.56 |
-20.04 |
-19.46 |
-1.76 |
-5.08 |
-5.12 |
-3.42 |
-3.08 |
| Weighted Average Shares Out |
$26.84 M
|
$26.51 M
|
$25.41 M
|
$22.44 M
|
$18.47 M
|
$12.97 M
|
$16.95 M
|
$16.62 M
|
$16.62 M
|
| Weighted Average Shares Out Diluted |
$26.84 M
|
$26.51 M
|
$25.41 M
|
$22.44 M
|
$18.47 M
|
$12.97 M
|
$16.95 M
|
$16.62 M
|
$16.62 M
|
| Link |
|
|
|
|
|
|
|
|
|
